芬拉胺:对德拉维特综合征和伦诺克斯-加斯托综合征的审查
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
低剂量芬拉胺 (Fintepla®) 有效治疗德拉维特综合征和伦诺克斯-加斯托综合征中的发作. 这种抗发作药物还改善了执行功能,而不会引起心脏或肺部问题.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床神经学 临床神经学
背景情况:
- 芬弗鲁拉胺 (Fintepla®) 之前因安全问题 (膜心脏病,肺动脉高血压) 而被撤销,剂量较高.
- 它具有一种新的机制,涉及到血清能系统和西格玛-1受体.
- 发育性脑病变,如德拉维特综合征和伦诺克斯-加斯托综合征,常常伴有抗药性发作.
研究的目的:
- 评估低剂量芬拉胺作为在德拉维特综合征 (DS) 和伦诺克斯-加斯托综合征 (LGS) 中抗药性发作的辅助抗发作药物 (ASM) 的疗效和安全性.
- 评估黄胺对执行功能 (EF) 的影响,除了减少发作之外.
主要方法:
- 临床试验涉及DS和LGS患者接受补充芬拉胺的患者.
- 减少发作频率的评估 (DS中的发作,LGS中的发作).
- 评估执行功能和安全,包括监测心脏膜疾病 (VHD) 和肺动脉高血压 (PAH).
主要成果:
- 补充芬拉胺显著降低了DS患者的发作频率 (持续长达3年).
- 辅助芬拉胺降低了LGS患者的发作频率 (持续长达1年).
- 观察到执行功能的改善,不仅仅归因于发作减少. 没有报告VHD或PAH事件.
结论:
- 低剂量的芬拉胺是一种有效且耐受良好的辅助治疗,用于DS和LGS中抗药性发作.
- 除了控制发作之外,芬拉胺还为执行功能提供了潜在的好处.
- 这些试验的安全性概况没有揭示先前相关的心脏或肺部风险.
更多相关视频
00:08Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
Published on: October 19, 2021
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drug Regulation
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
